Quantitative PET and histology of brain biopsy reveal lack of selective Pittsburgh compound-B binding to intracerebral amyloidoma

Manuscript Number: 

18-0316R2

Author(s): 
Frederik Barkhof, Baayla D.C. Boon, Colin Groot, Milos D. Ikonomovic, William E. Klunk, Adriaan Lammertsma, Rik Ossenkoppele, Annemieke J. Rozemuller, Philip Scheltens, Nelleke Tolboom, Bart N. van Berckel

Disclosures

Frederik Barkhof

  • Nothing to Disclose

Baayla D.C. Boon

  • Nothing to Disclose

Colin Groot

  • Nothing to Disclose

Milos D. Ikonomovic

  • Consulting Fees:
    Unrelated to this work, received consulting fees from GE Healthcare.

William E. Klunk

  • Patents/Royalties
    Named inventor on patents related to PiB PET technology owned by the University of Pittsburgh and licensed to GE Healthcare.

Adriaan Lammertsma

  • Nothing to Disclose

Rik Ossenkoppele

  • Nothing to Disclose

Annemieke J. Rozemuller

  • Nothing to Disclose

Philip Scheltens

  • Nothing to Disclose

Nelleke Tolboom

  • Nothing to Disclose

Bart N. van Berckel

  • Consulting Fees:
    He is a trainer for Piramal Neuroimaging, GE and AVID Radiopharmaceuticals. All funding is paid to his institution.
    Lecture Fees:
    Trainer for Piramal Neuroimaging, GE and AVID Radiopharmaceuticals. All funding is paid to his institution.
    Grants
    • Agency: 
      Alzheimer Association
    • Agency: 
      American Health Assistance Foundation
    • Agency: 
      Alzheimer Nederland
    • Agency: 
      CTMM
    • Agency: 
      ZonMW
    • Agency: 
      Janssen Stellar
    • Agency: 
      AVID Radiopharmaceuticals
    • Agency: 
      NOW
    • Agency: 
      EU-FP7